Drug intelligence / Profile preview

rhMMP-7

Development stage
Preclinical
Lead developer
Teikoku Seiyaku
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Percutaneous
01

Overview

rhMMP-7 (KTP-001) is a recombinant human matrix metalloproteinase-7 (MMP-7) being developed by Teikoku Seiyaku for the treatment of lumbar disc herniation. As a recombinant protease, rhMMP-7 is designed to be administered locally to enzymatically degrade the extracellular matrix components of the herniated nucleus pulposus, thereby reducing the size of the herniation and alleviating pressure on spinal nerves. The drug is produced using microbial manufacturing processes, with AGC Biologics serving as the contract development and manufacturing organization (CDMO) for clinical supply. It represents a non-surgical, enzymatic approach to treating degenerative disc disease.

Other names
recombinant human matrix metalloproteinase-7recombinant human MMP-7
02

Targets

Lipid membraneCD151 (CD151 molecule (Raph blood group))NP-ECM (Extracellular matrix components of herniated nucleus pulposus/disc tissue)SulfatideSDC2 (Syndecan-2)Matrix metalloproteinase-2 (MMP-2) and Matrix metalloproteinase-9 (MMP-9)

Beyond the preview

Go deeper on rhMMP-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rhMMP-7.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call